Trial intelligence / Profile preview

Corticosteroids Prophylaxis for Mylotarg in AML

NCT00304447Phase 4Completed

Sponsor
Pfizer
Start
Apr 2002
Modality
Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01

Overview

A Phase 4 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Pfizer. Started Apr 2002; status: completed.

02

Drugs

gemtuzumab ozogamicin
03

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on NCT00304447.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00304447.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call